245 related articles for article (PubMed ID: 11475342)
21. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients.
Ota K; Akiba T; Nakao T; Nakayama M; Maeba T; Park MS; Tranaeus A; Yorioka N;
Perit Dial Int; 2003; 23(4):356-61. PubMed ID: 12968843
[TBL] [Abstract][Full Text] [Related]
22. Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids.
Glorieux G; Lameire N; Van Biesen W; Dequidt C; Vanholder R
Nephrol Dial Transplant; 2003 Aug; 18(8):1648-53. PubMed ID: 12897108
[TBL] [Abstract][Full Text] [Related]
23. Icodextrin and intraperitoneal inflammation.
Moriishi M; Kawanishi H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
[TBL] [Abstract][Full Text] [Related]
24. Automated peritoneal dialysis prescriptions for enhancing sodium and fluid removal: a predictive analysis of optimized, patient-specific dwell times for the day period.
Akonur A; Guest S; Sloand JA; Leypoldt JK
Perit Dial Int; 2013; 33(6):646-54. PubMed ID: 24335125
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis.
Plum J; Gentile S; Verger C; Brunkhorst R; Bahner U; Faller B; Peeters J; Freida P; Struijk DG; Krediet RT; Grabensee B; Tranaeus A; Filho JC
Am J Kidney Dis; 2002 Apr; 39(4):862-71. PubMed ID: 11920355
[TBL] [Abstract][Full Text] [Related]
26. High peritoneal residual volume decreases the efficiency of peritoneal dialysis.
Wang T; Cheng HH; Heimbürger O; Bergström J; Lindholm B
Kidney Int; 1999 May; 55(5):2040-8. PubMed ID: 10231469
[TBL] [Abstract][Full Text] [Related]
27. Enhanced ultrafiltration using 7.5% icodextrin/1.36% glucose combination dialysate: a pilot study.
Dallas F; Jenkins SB; Wilkie ME
Perit Dial Int; 2004; 24(6):542-6. PubMed ID: 15559483
[TBL] [Abstract][Full Text] [Related]
28. Factors affecting bicarbonate transfer with bicarbonate-containing CAPD solution.
Feriani M; Passlick-Deetjen J; La Greca G
Perit Dial Int; 1995; 15(8):336-41. PubMed ID: 8785231
[TBL] [Abstract][Full Text] [Related]
29. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
[TBL] [Abstract][Full Text] [Related]
30. [Peritoneal equilibrium test using icodextrin and glucose at different concentrations].
Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Gallego T; Delgado-Pecellín C; Benítez M; Torán CD
Nefrologia; 2002; 22(4):340-7. PubMed ID: 12369125
[TBL] [Abstract][Full Text] [Related]
31. Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell.
Freida P; Galach M; Divino Filho JC; Werynski A; Lindholm B
Perit Dial Int; 2007; 27(3):267-76. PubMed ID: 17468474
[TBL] [Abstract][Full Text] [Related]
32. Icodextrin with nitroprusside increases ultrafiltration and peritoneal transport during long CAPD dwells.
Douma CE; Hiralall JK; de Waart DR; Struijk DG; Krediet RT
Kidney Int; 1998 Apr; 53(4):1014-21. PubMed ID: 9551412
[TBL] [Abstract][Full Text] [Related]
33. Icodextrin: a review of its use in peritoneal dialysis.
Frampton JE; Plosker GL
Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
[TBL] [Abstract][Full Text] [Related]
34. Rate of synthetic oligosaccharide degradation as a novel measure of amylase activity in peritoneal dialysis patients.
García-López E; Werynski A; Heimbürger O; Filho JC; Lindholm B; Anderstam B
Perit Dial Int; 2008; 28(3):296-304. PubMed ID: 18474923
[TBL] [Abstract][Full Text] [Related]
35. Factors related to ultrafiltration volume with icodextrin dialysate use in children.
Mikami N; Hamada R; Harada R; Hamasaki Y; Ishikura K; Honda M; Hataya H
Pediatr Nephrol; 2023 Apr; 38(4):1267-1273. PubMed ID: 36053354
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal clearance of homocysteine with icodextrin or standard glucose solution exchange.
Czupryniak A; Nowicki M; Chwatko G; Jander A; Bald E
Nephrology (Carlton); 2005 Dec; 10(6):571-5. PubMed ID: 16354239
[TBL] [Abstract][Full Text] [Related]
37. The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test.
Araújo Teixeira MR; Pecoits-Filho RF; Romão Junior JE; Sabbaga E; Marcondes MM; Abensur H
Perit Dial Int; 2002; 22(2):229-33. PubMed ID: 11990408
[TBL] [Abstract][Full Text] [Related]
38. Kinetic analysis of peritoneal fluid and solute transport with combination of glucose and icodextrin as osmotic agents.
Galach M; Werynski A; Waniewski J; Freida P; Lindholm B
Perit Dial Int; 2009; 29(1):72-80. PubMed ID: 19164256
[TBL] [Abstract][Full Text] [Related]
39. Volume-Based Peritoneal Dialysis Prescription Guide to Achieve Adequacy Targets.
Akonur A; Firanek CA; Gellens ME; Hutchcraft AM; Kathuria P; Sloand JA
Perit Dial Int; 2016; 36(2):188-95. PubMed ID: 26293841
[TBL] [Abstract][Full Text] [Related]
40. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.
le Poole CY; Welten AG; Weijmer MC; Valentijn RM; van Ittersum FJ; ter Wee PM
Perit Dial Int; 2005 Feb; 25 Suppl 3():S64-8. PubMed ID: 16048260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
